Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0939920020340060426
´ëÇѾÏÇÐȸÁö
2002 Volume.34 No. 6 p.426 ~ p.431
SB203580, a P38 MAPK Inhibitor, Blocks in vitro Invasion by Human Gastric SNU-638 Cells
Park Ju-Chae

Yoo Hyeon-Gyeung
Kim Hong-Su
Chung Min-A
Kim Mi-Ha
Han Sang-Won
Chay Kee-Oh
Shin Boo-Ahn
Ahn Bong-Whan
Jung Young-Do
Abstract
Purpose: The role of P38 mitogen-activated protein kinase (MAPK) in gastric cancer invasion has not yet been determined. In this study, we examined the effects of SB203580, a specific P38 MAPK inhibitor, on the in vitro invasion of gastric
cancer
and upon the molecules involved in this process.

Materials and Methods: Human gastric cancer SNU-638 cells were maintained in RPMI 1640 supplemented with 10% FBS. BIOCOAT matrigel invasion chambers were used to examine in vitro invasiveness, zymography for gelatinase activity, CAT assay
for uPA
promoter activity and Western and Northern blotting to determine protein and mRNA levels, respectively.

Results: Treatment of SNU-638 cells with SB203580, a specific P38 MAPK inhibitor, reduced in vitro invasiveness, dose-dependently. SB203580 treatment was found to decrease both mRNA expression and uPA promoter activity in gastric SNU-638
cells.
In vitro invasion of SNU-638 cells was partially abrogated by uPA-neutralizing antibodies. The activities of MMPs were not significantly altered by SB203580.

Conclusion: Our results suggest that P38 MAPK is a potential therapeutic target for inhibiting uPA-dependent gastric tumor invasiveness and metastasis.
KEYWORD
Stomach neoplasm, P38 milogen-activated protein kinase, Urokinase-type plasminigen activator, Invasion
FullTexts / Linksout information
  
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø